Department of Biosciences, University of Salzburg, Austria.
VIB-VUB Center for Structural Biology, Brussels, Belgium.
FEBS Open Bio. 2019 Aug;9(8):1370-1378. doi: 10.1002/2211-5463.12653. Epub 2019 Jul 2.
Blood coagulation involves extrinsic and intrinsic pathways, which merge at the activation step of blood coagulation factor X to factor Xa. This step is catalysed by the extrinsic or intrinsic Xase, which consists of a complex of factor VIIa and its cofactor tissue factor or factor IXa (FIXa) and its cofactor coagulation factor VIIIa (FVIIIa). Upon complex formation with FVIIIa, FIXa is conformationally activated to the Xase complex. However, the mechanistic understanding of this molecular recognition is limited. Here, we examined FVIIIa-FIXa binding in the context of FIXa's activation status. Given the complexity and the labile nature of FVIIIa, we decided to employ two FVIII-derived peptides (558-loop, a2 peptide) to model the cofactor binding of FIX(a) using biosensor chip technology. These two FVIII peptides are known to mediate the key interactions between FVIIIa and FIXa. We found both of these cofactor mimetics as well as full-length FVIIIa bind more tightly to zymogenic FIX than to proteolytically activated FIXa. Consequently and surprisingly, we observed that the catalytically inactive FIX zymogen can outcompete the activated FIXa from the complex with FVIIIa, resulting in an inactive, zymogenic Xase complex. By contrast, the thrombophilic Padua mutant FIXa-R170 in complex with the protein-substrate analogue BPTI bound tighter to FVIIIa than to the zymogen form FIX-R170L, suggesting that the active Xase complex preferentially forms in the Padua variant. Together, these results provide a mechanistic basis for the thrombophilic nature of the FIX-R170L mutant and suggest the existence of a newly discovered safety measure within the coagulation cascade.
血液凝固涉及外源性和内源性途径,它们在外源性凝血因子 VIIa 和其辅因子组织因子或内源性凝血因子 IXa (FIXa) 和其辅因子凝血因子 VIIIa (FVIIIa) 的激活步骤处合并。这一步骤由外源性或内源性 X 酶催化,该酶由因子 VIIa 与其辅因子组织因子或因子 IXa (FIXa) 和其辅因子凝血因子 VIIIa (FVIIIa) 的复合物组成。在与 FVIIIa 形成复合物后,FIXa 构象激活为 X 酶复合物。然而,这种分子识别的机制理解有限。在这里,我们研究了 FIXa 激活状态下 FVIIIa-FIXa 结合。考虑到 FVIIIa 的复杂性和不稳定性,我们决定使用生物传感器芯片技术使用两种源自 FVIII 的肽 (558 环肽、a2 肽) 来模拟 FIX(a) 的辅因子结合。这两种 FVIII 肽已知介导 FVIIIa 和 FIXa 之间的关键相互作用。我们发现这两种辅因子模拟物以及全长 FVIIIa 与酶原形式的 FIX 结合比与蛋白水解激活的 FIXa 结合更紧密。出乎意料的是,我们观察到无活性的酶原 FIX 可以从 FVIIIa 与 FIXa 的复合物中与激活的 FIXa 竞争,导致无活性的酶原 X 酶复合物。相比之下,与蛋白底物类似物 BPTI 复合的具有血栓形成倾向的帕多瓦突变 FIXa-R170 与 FVIIIa 的结合比与酶原形式 FIX-R170L 的结合更紧密,这表明活性 X 酶复合物优先在帕多瓦变体中形成。总之,这些结果为 FIX-R170L 突变体的血栓形成倾向提供了机制基础,并表明凝血级联中存在新发现的安全措施。